Supplementary Table 1. Unadjusted association between hospitalization and selected cofactors.

| Factor | Hospitalization |  |  |
| :---: | :---: | :---: | :---: |
|  | No | Yes | $p$-value |
| N | 21 | 61 |  |
| Age, mean (SD) | 45.71 (14.38) | 58.16 (17.34) | 0.004 |
| BMI, mean (SD) | 29.17 (4.63) | 30.08 (5.94) | 0.55 |
| Maximum body temperature recorded, mean (SD) | 37.32 (0.59) | 38.57 (1.09) | <0.001 |
| Respiratory rate (highest), mean (SD) | 18.44 (1.82) | 36.90 (19.04) | <0.001 |
| Systolic, mean (SD) | 119.69 (19.11) | 91.32 (27.64) | <0.001 |
| Diastolic, mean (SD) | 71.44 (11.26) | 52.13 (15.42) | <0.001 |
| Lowest SpO2 recorded, mean (SD) | 94.44 (1.75) | 78.64 (18.32) | <0.001 |
| Hb , mean (SD) | 14.28 (2.08) | 12.26 (3.07) | 0.028 |
| WBC count, median (IQR) | 5.58 (5.05, 7.77) | 9.61 (4.97, 14.21) | 0.20 |
| Lymphocyte count, median (IQR) | 1.30 (0.98, 1.62) | 0.69 (0.49, 1.07) | 0.009 |
|  | 215.00 (196.00, | 244.00 (167.00, |  |
| Platelet count , median (IQR) | 279.00) | 390.00) | 0.42 |
| LDH, mean (SD) | NA | 641.77 (1325.41) |  |
| CRP, mean (SD) | NA | 11.82 (6.07) |  |
| Procalcitonin, mean (SD) | 0.05 (.) | 1.49 (4.42) |  |
| Lactic acid , mean (SD) | 3.20 (.) | 3.59 (7.09) |  |
| HCO3, mean (SD) | 23.14 (2.57) | 22.18 (11.83) | 0.76 |
|  | 34.00 (24.00, |  |  |
| AST, median (IQR) | 50.00) | 65.00 (44.00, 114.50) | 0.004 |
|  | 32.00 (22.00, |  |  |
| ALT, median (IQR) | 43.00) | 46.50 (31.00, 83.00) | 0.14 |
| INR, mean (SD) | 1.00 (.) | 1.68 (1.91) | 0.73 |
| PTT, mean (SD) | 26.00 (.) | 37.51 (22.89) | 0.63 |
| Bil total, median (IQR) | 0.75 (0.60, 0.90) | 0.80 (0.60, 1.10) | 0.52 |
| CK, mean (SD) | . (.) | 150.00 (180.32) |  |
| Na , mean (SD) | 137.29 (3.87) | 133.24 (18.14) | 0.41 |
| $K$, median (IQR) | 4.10 (3.90, 4.20) | 4.40 (3.60, 5.00) | 0.32 |
|  | 103.50 (100.00, |  |  |
| Cl, median (IQR) | 105.00) | 104.00 (96.00, 109.00) | 0.74 |
| D-Dimer, mean (SD) | . (.) | 43.93 (285.29) |  |
| PRO-BNP, mean (SD) | 49.00 (.) | 21666.63 (46063.72) | 0.66 |
| Lipase, mean (SD) | . (.) | 1564.70 (2866.79) |  |
| TROPONIN, mean (SD) | 0.01 (0.00) | 0.53 (2.93) | 0.57 |
| pH , mean (SD) | . (.) | 7.32 (0.17) |  |
| PO2, mean (SD) | . (.) | 59.44 (22.98) |  |
| PCO2, mean (SD) | . (.) | 43.17 (22.24) |  |
| Sex |  |  | 0.30 |
| F | 11 (52.4\%) | 24 (39.3\%) |  |
| M | 10 (47.6\%) | 37 (60.7\%) |  |


| Pregnancy | 0 (0.0\%) | 2 (3.3\%) | 0.40 |
| :---: | :---: | :---: | :---: |
| Current smokers | 1 (4.8\%) | 3 (4.9\%) | 0.98 |
| Drug use | 0 (0.0\%) | 3 (4.9\%) | 0.30 |
| IVDU | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| Alcoholic | 0 (0.0\%) | 3 (5.0\%) | 0.30 |
| Recent travel to infected region | 5 (23.8\%) | 18 (29.5\%) | 0.62 |
| Recent contact with COVID-19 + case | 3 (14.3\%) | 14 (23.0\%) | 0.40 |
| Duration between exposure and symptoms if known |  |  | 0.20 |
| 0 | 20 (95.2\%) | 60 (98.4\%) |  |
| 2 | 1 (4.8\%) | 0 (0.0\%) |  |
| 7 | 0 (0.0\%) | 1 (1.6\%) |  |
| Any positive family member/roommate | 5 (23.8\%) | 11 (18.0\%) | 0.56 |
| Any episode of fever | 10 (47.6\%) | 50 (82.0\%) | 0.002 |
| What was the first started symptom? |  |  | 0.63 |
| AMS | 0 (0.0\%) | 1 (1.6\%) |  |
| Anosmia | 1 (4.8\%) | 0 (0.0\%) |  |
| Cough | 0 (0.0\%) | 1 (1.6\%) |  |
| Hypoxia | 0 (0.0\%) | 1 (1.6\%) |  |
| SOB | 1 (4.8\%) | 2 (3.3\%) |  |
| Shortness of breath | 1 (4.8\%) | 6 (9.8\%) |  |
| abdominal pain | 0 (0.0\%) | 1 (1.6\%) |  |
| anosmia and ageusia | 0 (0.0\%) | 1 (1.6\%) |  |
| body aches | 1 (4.8\%) | 0 (0.0\%) |  |
| coffee-ground emesis | 0 (0.0\%) | 1 (1.6\%) |  |
| cough | 6 (28.6\%) | 10 (16.4\%) |  |
| cough \& headache | 0 (0.0\%) | 1 (1.6\%) |  |
| cough and SOB | 0 (0.0\%) | 1 (1.6\%) |  |
| cough and fever | 0 (0.0\%) | 1 (1.6\%) |  |
| cough or fever | 0 (0.0\%) | 1 (1.6\%) |  |
| diarrhea | 0 (0.0\%) | 1 (1.6\%) |  |
| dry cough | 0 (0.0\%) | 1 (1.6\%) |  |
| epigastric pain | 0 (0.0\%) | 1 (1.6\%) |  |
| fatigue | 0 (0.0\%) | 2 (3.3\%) |  |
| fatigue/weakness | 0 (0.0\%) | 1 (1.6\%) |  |
| fever | 2 (9.5\%) | 2 (3.3\%) |  |
| itchy throat | 1 (4.8\%) | 0 (0.0\%) |  |
| left-sided weakness | 0 (0.0\%) | 1 (1.6\%) |  |
| loss of taste and smell | 1 (4.8\%) | 0 (0.0\%) |  |
| nasal congestion | 0 (0.0\%) | 1 (1.6\%) |  |
| productive cough | 0 (0.0\%) | 1 (1.6\%) |  |
| sore throat | 1 (4.8\%) | 0 (0.0\%) |  |
| throat pain | 1 (4.8\%) | 0 (0.0\%) |  |
| weakness | 0 (0.0\%) | 1 (1.6\%) |  |
| weakness/fatigue | 0 (0.0\%) | 1 (1.6\%) |  |


|  | 5 (23.8\%) | 20 (32.8\%) |  |
| :---: | :---: | :---: | :---: |
| N_symptoms, mean (SD) | 4.29 (2.74) | 4.82 (2.97) | 0.47 |
| Conjunctival congestion |  |  |  |
| No | 21 (100.0\%) | 61 (100.0\%) |  |
| Nasal congestion | 8 (38.1\%) | 4 (6.6\%) | <0.001 |
| Rhinorrhea | 0 (0.0\%) | 3 (4.9\%) | 0.30 |
| Headache | 8 (38.1\%) | 18 (30.0\%) | 0.49 |
| Cough | 14 (66.7\%) | 41 (67.2\%) | 0.96 |
| Sore throat | 7 (33.3\%) | 11 (18.0\%) | 0.14 |
| Sputum production | 3 (14.3\%) | 8 (13.1\%) | 0.89 |
| Fatigue | 6 (28.6\%) | 31 (50.8\%) | 0.077 |
| Hemoptysis | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| Shortness of breath | 10 (47.6\%) | 45 (73.8\%) | 0.028 |
| chest pain | 5 (23.8\%) | 19 (31.1\%) | 0.52 |
| chest discomfort | 0 (0.0\%) | 12 (19.7\%) | 0.028 |
| abdominal pain | 0 (0.0\%) | 8 (13.1\%) | 0.081 |
| Nausea or vomiting | 4 (19.0\%) | 23 (37.7\%) | 0.12 |
| Diarrhea | 3 (14.3\%) | 17 (28.3\%) | 0.20 |
| Myalgia or arthralgia | 9 (42.9\%) | 21 (34.4\%) | 0.49 |
| Chill | 7 (33.3\%) | 20 (32.8\%) | 0.96 |
| loss of taste | 3 (14.3\%) | 6 (9.8\%) | 0.57 |
| loss of smell | 3 (14.3\%) | 6 (9.8\%) | 0.57 |
| N_signs, mean (SD) | 0.29 (0.64) | 0.56 (0.65) | 0.10 |
| N_signs |  |  | 0.038 |
| 0 | 17 (81.0\%) | 32 (52.5\%) |  |
| 1 | 2 (9.5\%) | 24 (39.3\%) |  |
| 2 | 2 (9.5\%) | 5 (8.2\%) |  |
| Throat congestion | 3 (14.3\%) | 0 (0.0\%) | 0.003 |
| Tonsil swelling | 1 (4.8\%) | 3 (4.9\%) | 0.98 |
| Rash | 1 (4.8\%) | 2 (3.3\%) | 0.75 |
| Abnormal lung sounds | 0 (0.0\%) | 27 (45.8\%) | <0.001 |
| N_chronic, mean (SD) | 0.67 (0.91) | 1.67 (1.33) | 0.002 |
| N_chronic |  |  | 0.062 |
| 0 | 12 (57.1\%) | 15 (24.6\%) |  |
| 1 | 5 (23.8\%) | 11 (18.0\%) |  |
| 2 | 3 (14.3\%) | 22 (36.1\%) |  |
| 3 | 1 (4.8\%) | 7 (11.5\%) |  |
| 4 | 0 (0.0\%) | 4 (6.6\%) |  |
| 5 | 0 (0.0\%) | 2 (3.3\%) |  |
| N_chronic1 |  |  | 0.017 |
| 0 | 12 (57.1\%) | 15 (24.6\%) |  |
| 1 | 5 (23.8\%) | 11 (18.0\%) |  |
| 2 | 3 (14.3\%) | 22 (36.1\%) |  |
| 33 | 1 (4.8\%) | 13 (21.3\%) |  |
| COPD | 0 (0.0\%) | 2 (3.3\%) | 0.40 |


| DM | 2 (9.5\%) | 30 (49.2\%) | 0.001 |
| :---: | :---: | :---: | :---: |
| HTN | 6 (28.6\%) | 34 (55.7\%) | 0.032 |
| Coronary artery disease | 0 (0.0\%) | 8 (13.1\%) | 0.081 |
| Cerebrovascular disease | 1 (4.8\%) | 5 (8.2\%) | 0.60 |
| Cancer | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| CKD | 0 (0.0\%) | 7 (11.5\%) | 0.10 |
| Cirrhosis | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| Asthma | 1 (4.8\%) | 3 (4.9\%) | 0.98 |
| Rheumatological | 1 (4.8\%) | 0 (0.0\%) | 0.086 |
| IBD | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| HIV+ | 0 (0.0\%) | 1 (1.6\%) | 0.55 |
| Hepatitis | 0 (0.0\%) | 2 (3.3\%) | 0.40 |
| Hypothyroidism | 3 (15.0\%) | 7 (11.5\%) | 0.68 |
| Hyperthyroidism |  |  |  |
| 0 | 21 (100.0\%) | 60 (98.4\%) |  |
|  | 0 (0.0\%) | 1 (1.6\%) |  |
| Ground-glass opacities |  |  | <0.001 |
| 0 | 10 (47.6\%) | 21 (34.4\%) |  |
| 1 | 4 (19.0\%) | 38 (62.3\%) |  |
| 99 | 7 (33.3\%) | 2 (3.3\%) |  |
| Local patchy shadowing |  |  | <0.001 |
| 0 | 11 (52.4\%) | 29 (47.5\%) |  |
| 1 | 3 (14.3\%) | 30 (49.2\%) |  |
| 99 | 7 (33.3\%) | 2 (3.3\%) |  |
| Diffuse patchy shadowing |  |  | <0.001 |
| 0 | 13 (61.9\%) | 31 (50.8\%) |  |
| 1 | 1 (4.8\%) | 28 (45.9\%) |  |
| 99 | 7 (33.3\%) | 2 (3.3\%) |  |
| Pleural effusion |  |  | <0.001 |
| 0 | 13 (61.9\%) | 42 (68.9\%) |  |
| 1 | 1 (4.8\%) | 17 (27.9\%) |  |
| 99 | 7 (33.3\%) | 2 (3.3\%) |  |
| Interstitial abnormalities |  |  | 0.001 |
| 0 | 13 (61.9\%) | 26 (42.6\%) |  |
| 1 | 1 (4.8\%) | 29 (47.5\%) |  |
| na | 7 (33.3\%) | 4 (6.6\%) |  |
| CT_Ground-glass opacities |  |  | 0.048 |
| 1 | 1 (4.8\%) | 15 (24.6\%) |  |
| na | 20 (95.2\%) | 46 (75.4\%) |  |
| CT_Local patchy shadowing |  |  | 0.23 |
| 0 | 0 (0.0\%) | 6 (9.8\%) |  |
| 1 | 1 (4.8\%) | 6 (9.8\%) |  |
| na | 20 (95.2\%) | 49 (80.3\%) |  |
| CT_Diffuse patchy shadowing |  |  | 0.28 |
| 0 | 1 (4.8\%) | 6 (9.8\%) |  |


| 1 | 0 (0.0\%) | 5 (8.2\%) |  |
| :---: | :---: | :---: | :---: |
| na | 20 (95.2\%) | 50 (82.0\%) |  |
| CT_Pleural effusion |  |  | 0.15 |
| 0 | 1 (4.8\%) | 6 (9.8\%) |  |
| 1 | 0 (0.0\%) | 8 (13.1\%) |  |
| na | 20 (95.2\%) | 47 (77.0\%) |  |
| CT_Interstitial abnormalities |  |  | 0.28 |
| 0 | 1 (4.8\%) | 6 (9.8\%) |  |
| 1 | 0 (0.0\%) | 7 (11.5\%) |  |
| 60 | 0 (0.0\%) | 1 (1.6\%) |  |
| na | 20 (95.2\%) | 47 (77.0\%) |  |
| N_med, mean (SD) | 0.86 (1.15) | 3.05 (2.12) | <0.001 |
| N_med |  |  | 0.005 |
| 0 | 11 (52.4\%) | 6 (9.8\%) |  |
| 1 | 5 (23.8\%) | 12 (19.7\%) |  |
| 2 | 3 (14.3\%) | 10 (16.4\%) |  |
| 3 | 1 (4.8\%) | 5 (8.2\%) |  |
| 4 | 1 (4.8\%) | 14 (23.0\%) |  |
| 5 | 0 (0.0\%) | 7 (11.5\%) |  |
| 6 | 0 (0.0\%) | 4 (6.6\%) |  |
| 7 | 0 (0.0\%) | 2 (3.3\%) |  |
| 10 | 0 (0.0\%) | 1 (1.6\%) |  |
| N_med1 |  |  | <0.001 |
| 0 | 11 (52.4\%) | 6 (9.8\%) |  |
| 1 | 5 (23.8\%) | 12 (19.7\%) |  |
| 2 | 3 (14.3\%) | 10 (16.4\%) |  |
| 3 | 1 (4.8\%) | 5 (8.2\%) |  |
| 4 | 1 (4.8\%) | 14 (23.0\%) |  |
| 5 | 0 (0.0\%) | 14 (23.0\%) |  |
| Remdesivir | 0 (0.0\%) | 4 (6.6\%) | 0.23 |
| Hydroxychloroquine | 0 (0.0\%) | 15 (24.6\%) | 0.012 |
| azithromycin | 10 (47.6\%) | 44 (72.1\%) | 0.041 |
| Statin | 2 (9.5\%) | 22 (36.1\%) | 0.021 |
| Corticosteroid | 3 (14.3\%) | 22 (36.1\%) | 0.061 |
| ACEi/ARB | 2 (9.5\%) | 8 (13.1\%) | 0.66 |
| Vit C | 1 (4.8\%) | 23 (37.7\%) | 0.004 |
| Zinc | 0 (0.0\%) | 21 (34.4\%) | 0.002 |
| Vitamin D | 0 (0.0\%) | 14 (23.0\%) | 0.016 |
| Vasopressors | 0 (0.0\%) | 9 (14.8\%) | 0.062 |
| Tocilizumab | 0 (0.0\%) | 2 (3.3\%) | 0.40 |
| convalescent plasma | 0 (0.0\%) | 2 (3.3\%) | 0.40 |

SD: standard deviation; IQR: Inter-quartile range

Suppl. Table 2. Unadjusted association between mortality and cofactors.

|  | Death |  | p -value |
| :---: | :---: | :---: | :---: |
| Factor | No | Yes |  |
| N | 67 | 15 |  |
| Age, mean (SD) | 51.67 (16.65) | 69.73 (12.81) | <0.001 |
| BMI, mean (SD) | 29.87 (5.16) | 29.86 (7.60) | 1.00 |
| Maximum body temperature recorded, mean (SD) | 38.02 (0.91) | 39.47 (1.21) | <0.001 |
| Respiratory rate (highest), mean (SD) | 26.66 (13.34) | 58.87 (13.55) | <0.001 |
| Systolic, mean (SD) | 105.77 (22.59) | 62.80 (23.72) | <0.001 |
| Diastolic, mean (SD) | 61.10 (12.74) | 36.27 (15.73) | <0.001 |
| Lowest SpO2 recorded, mean (SD) | 87.58 (11.07) | 58.53 (20.14) | <0.001 |
| Hb , mean (SD) | 13.06 (3.02) | 10.88 (2.35) | 0.011 |
|  |  | 16.05 (11.88, |  |
| WBC count, median (IQR) | 6.93 (4.45, 11.43) | 29.00) | <0.001 |
| Lymphocyte count, median (IQR) | 0.86 (0.60, 1.30) | 0.51 (0.37, 0.69) | <0.001 |
|  | 236.00 (176.00, | 305.00 (114.00, |  |
| Platelet count, median (IQR) | 334.00) | 474.00) | 0.89 |
|  | 353.00 (237.00, | 677.00 (653.00, |  |
| LDH, median (IQR) | 447.00) | 952.00) | <0.001 |
|  | $13.30 \text { (5.90, }$ | $18.00 \text { (11.05, }$ |  |
| CRP, median (IQR) | 17.30) | 18.00) | 0.026 |
| Procalcitonin, median (IQR) | 0.11 (0.05, 0.23) | 0.33 (0.16, 0.52) | 0.022 |
| Lactic acid, median (IQR) | 1.15 (0.80, 2.00) | 3.15 (1.60, 5.80) | 0.004 |
| HCO3, mean (SD) | 22.61 (10.65) | 21.40 (11.19) | 0.70 |
|  | $53.50 \text { (34.00, }$ | $136.00(74.00,$ |  |
| AST, median (IQR) | 72.00) | $376.00)$ | <0.001 |
|  | $42.50 \text { (22.00, }$ | $83.00 \text { (40.00, }$ |  |
| ALT, median (IQR) | 65.00) | 157.00) | 0.011 |
| INR , median (IQR) | 1.20 (1.10, 1.30) | 1.40 (1.20, 1.50) | 0.042 |
|  | 31.00 (24.70, | 41.30 (33.10, |  |
| PTT, median (IQR) | 33.40) | 88.10) | 0.007 |
| Bil total, median (IQR) | 0.75 (0.60, 1.00) | 0.90 (0.70, 2.20) | 0.025 |
| CK, mean (SD) | 150.00 (180.32) | . (.) |  |
| Na , mean (SD) | 132.28 (17.24) | 140.87 (11.08) | 0.071 |
| K , median (IQR) | 4.10 (3.65, 4.70) | 5.40 (3.50, 6.30) | 0.037 |
|  | 103.00 (97.00, | 112.00 (95.00, |  |
| Cl , median (IQR) | 107.00) | 115.00) | 0.008 |
| D-Dimer, median (IQR) | $1.10(0.63,2.20)$ | 3.80 (2.63, 11.23) | 0.002 |
|  | $299.50 \text { (106.00, }$ | $1010.00$ |  |
| PRO-BNP, median (IQR) | 887.00) | 28700.00) | 0.20 |
| Lipase, mean (SD) | 169.72 (142.66) | 4819.67 (3770.82) | 0.007 |
| TROPONIN, median (IQR) | 0.01 (0.01, 0.01) | 0.03 (0.01, 0.11) | 0.002 |
| pH , mean (SD) | 7.40 (0.09) | 7.24 (0.19) | 0.009 |


|  | $61.20 \text { (55.30, }$ | $47.60 \text { (46.30, }$ |  |
| :---: | :---: | :---: | :---: |
| PO2, median (IQR) | 70.50) | 61.80) | 0.36 |
|  | 32.70 (28.60, | $55.80 \text { (33.20, }$ |  |
| PCO2, median (IQR) | 39.50) | 60.50) | 0.060 |
| Sex |  |  | 0.17 |
| F | 31 (46.3\%) | 4 (26.7\%) |  |
| M | 36 (53.7\%) | 11 (73.3\%) |  |
| Pregnancy | 2 (3.0\%) | 0 (0.0\%) | 0.50 |
| Current smokers | 4 (6.0\%) | 0 (0.0\%) | 0.33 |
| Drug use | 3 (4.5\%) | 0 (0.0\%) | 0.40 |
| IVDU | 1 (1.5\%) | 0 (0.0\%) | 0.63 |
| Alcoholic | 2 (3.0\%) | 1 (6.7\%) | 0.50 |
| Recent travel to infected region | 18 (26.9\%) | 5 (33.3\%) | 0.61 |
| Recent contact with COVID-19 + case | 12 (17.9\%) | 5 (33.3\%) | 0.18 |
| Duration between exposure and symptoms if known |  |  | 0.79 |
| 0 | 65 (97.0\%) | 15 (100.0\%) |  |
| 2 | 1 (1.5\%) | 0 (0.0\%) |  |
| 7 | 1 (1.5\%) | 0 (0.0\%) |  |
| Any positive family member/roommate | 13 (19.4\%) | 3 (20.0\%) | 0.96 |
| Any episode of fever | 47 (70.1\%) | 13 (86.7\%) | 0.19 |
| What was the first started symptom? |  |  | 0.23 |
| AMS | 1 (1.5\%) | 0 (0.0\%) |  |
| Anosmia | 1 (1.5\%) | 0 (0.0\%) |  |
| Cough | 1 (1.5\%) | 0 (0.0\%) |  |
| Hypoxia | 0 (0.0\%) | 1 (6.7\%) |  |
| SOB | 2 (3.0\%) | 1 (6.7\%) |  |
| Shortness of breath | 5 (7.5\%) | 2 (13.3\%) |  |
| abdominal pain | 0 (0.0\%) | 1 (6.7\%) |  |
| anosmia and ageusia | 1 (1.5\%) | 0 (0.0\%) |  |
| body aches | 1 (1.5\%) | 0 (0.0\%) |  |
| coffee-ground emesis | 0 (0.0\%) | 1 (6.7\%) |  |
| cough | 15 (22.4\%) | 1 (6.7\%) |  |
| cough \& headache | 1 (1.5\%) | 0 (0.0\%) |  |
| cough and SOB | 1 (1.5\%) | 0 (0.0\%) |  |
| cough and fever | 0 (0.0\%) | 1 (6.7\%) |  |
| cough or fever | 1 (1.5\%) | 0 (0.0\%) |  |
| diarrhea | 1 (1.5\%) | 0 (0.0\%) |  |
| dry cough | 1 (1.5\%) | 0 (0.0\%) |  |
| epigastric pain | 1 (1.5\%) | 0 (0.0\%) |  |
| fatigue | 2 (3.0\%) | 0 (0.0\%) |  |
| fatigue/weakness | 1 (1.5\%) | 0 (0.0\%) |  |
| fever | 3 (4.5\%) | 1 (6.7\%) |  |
| itchy throat | 1 (1.5\%) | 0 (0.0\%) |  |
| left-sided weakness | 0 (0.0\%) | 1 (6.7\%) |  |
| loss of taste and smell | 1 (1.5\%) | 0 (0.0\%) |  |


| nasal congestion | 1 (1.5\%) | 0 (0.0\%) |  |
| :---: | :---: | :---: | :---: |
| productive cough | 1 (1.5\%) | 0 (0.0\%) |  |
| sore throat | 1 (1.5\%) | 0 (0.0\%) |  |
| throat pain | 1 (1.5\%) | 0 (0.0\%) |  |
| weakness | 0 (0.0\%) | 1 (6.7\%) |  |
| weakness/fatigue | 0 (0.0\%) | 1 (6.7\%) |  |
|  | 22 (32.8\%) | 3 (20.0\%) |  |
| N_symptoms, mean (SD) | 5.13 (2.91) | 2.67 (1.91) | 0.002 |
| Conjunctival congestion |  |  |  |
| 0 | 67 (100.0\%) | 15 (100.0\%) |  |
| Nasal congestion | 12 (17.9\%) | 0 (0.0\%) | 0.076 |
| Rhinorrhea | 3 (4.5\%) | 0 (0.0\%) | 0.40 |
| Headache | 24 (36.4\%) | 2 (13.3\%) | 0.085 |
| Cough | 48 (71.6\%) | 7 (46.7\%) | 0.063 |
| Sore throat | 17 (25.4\%) | 1 (6.7\%) | 0.11 |
| Sputum production | 10 (14.9\%) | 1 (6.7\%) | 0.40 |
| Fatigue | 31 (46.3\%) | 6 (40.0\%) | 0.66 |
| Hemoptysis | 1 (1.5\%) | 0 (0.0\%) | 0.63 |
| Shortness of breath | 46 (68.7\%) | 9 (60.0\%) | 0.52 |
| chest pain | 23 (34.3\%) | 1 (6.7\%) | 0.033 |
| chest discomfort | 12 (17.9\%) | 0 (0.0\%) | 0.076 |
| abdominal pain | 5 (7.5\%) | 3 (20.0\%) | 0.14 |
| Nausea or vomiting | 22 (32.8\%) | 5 (33.3\%) | 0.97 |
| Diarrhea | 17 (25.8\%) | 3 (20.0\%) | 0.64 |
| Myalgia or arthralgia | 29 (43.3\%) | 1 (6.7\%) | 0.008 |
| Chill | 26 (38.8\%) | 1 (6.7\%) | 0.017 |
| loss of taste | 9 (13.4\%) | 0 (0.0\%) | 0.13 |
| loss of smell | 9 (13.4\%) | 0 (0.0\%) | 0.13 |
| N_signs, mean (SD) | 0.48 (0.68) | 0.53 (0.52) | 0.77 |
| N_signs |  |  | 0.091 |
| 0 | 42 (62.7\%) | 7 (46.7\%) |  |
| 1 | 18 (26.9\%) | 8 (53.3\%) |  |
| 2 | 7 (10.4\%) | 0 (0.0\%) |  |
| Throat congestion | 3 (4.5\%) | 0 (0.0\%) | 0.40 |
| Tonsil swelling | 4 (6.0\%) | 0 (0.0\%) | 0.33 |
| Rash | 3 (4.5\%) | 0 (0.0\%) | 0.40 |
| Abnormal lung sounds | 19 (29.2\%) | 8 (53.3\%) | 0.075 |
| N_chronic, mean (SD) | 1.21 (1.27) | 2.33 (1.05) | 0.002 |
| N_chronic |  |  | 0.008 |
| 0 | 26 (38.8\%) | 1 (6.7\%) |  |
| 1 | 15 (22.4\%) | 1 (6.7\%) |  |
| 2 | 18 (26.9\%) | 7 (46.7\%) |  |
| 3 | 4 (6.0\%) | 4 (26.7\%) |  |
| 4 | 2 (3.0\%) | 2 (13.3\%) |  |
| 5 | 2 (3.0\%) | 0 (0.0\%) |  |


| N_chronic1 |  |  | 0.006 |
| :---: | :---: | :---: | :---: |
| 0 | 26 (38.8\%) | 1 (6.7\%) |  |
| 1 | 15 (22.4\%) | 1 (6.7\%) |  |
| 2 | 18 (26.9\%) | 7 (46.7\%) |  |
| 33 | 8 (11.9\%) | 6 (40.0\%) |  |
| COPD | 2 (3.0\%) | 0 (0.0\%) | 0.50 |
| DM | 21 (31.3\%) | 11 (73.3\%) | 0.003 |
| HTN | 29 (43.3\%) | 11 (73.3\%) | 0.035 |
| Coronary artery disease | 5 (7.5\%) | 3 (20.0\%) | 0.14 |
| Cerebrovascular disease | 4 (6.0\%) | 2 (13.3\%) | 0.32 |
| Cancer | 1 (1.5\%) | 0 (0.0\%) | 0.63 |
| CKD | 4 (6.0\%) | 3 (20.0\%) | 0.079 |
| Cirrhosis | 1 (1.5\%) | 0 (0.0\%) | 0.63 |
| Asthma | 3 (4.5\%) | 1 (6.7\%) | 0.72 |
| Rheumatological | 1 (1.5\%) | 0 (0.0\%) | 0.63 |
| IBD | 0 (0.0\%) | 1 (6.7\%) | 0.033 |
| HIV+ | 0 (0.0\%) | 1 (6.7\%) | 0.033 |
| Hepatitis | 2 (3.0\%) | 0 (0.0\%) | 0.50 |
| Hypothyroidism | 8 (12.1\%) | 2 (13.3\%) | 0.90 |
| Hyperthyroidism |  |  |  |
| 0 | 67 (100.0\%) | 14 (93.3\%) |  |
|  | 0 (0.0\%) | 1 (6.7\%) |  |
| Ground-glass opacities |  |  | 0.009 |
| 0 | 29 (43.3\%) | 2 (13.3\%) |  |
| 1 | 29 (43.3\%) | 13 (86.7\%) |  |
| 99 | 9 (13.4\%) | 0 (0.0\%) |  |
| Local patchy shadowing |  |  | 0.29 |
| 0 | 31 (46.3\%) | 9 (60.0\%) |  |
| 1 | 27 (40.3\%) | 6 (40.0\%) |  |
| 99 | 9 (13.4\%) | 0 (0.0\%) |  |
| Diffuse patchy shadowing |  |  | <0.001 |
| 0 | 41 (61.2\%) | 3 (20.0\%) |  |
| 1 | 17 (25.4\%) | 12 (80.0\%) |  |
| 99 | 9 (13.4\%) | 0 (0.0\%) |  |
| Pleural effusion |  |  | <0.001 |
| 0 | 50 (74.6\%) | 5 (33.3\%) |  |
| 1 | 8 (11.9\%) | 10 (66.7\%) |  |
| 99 | 9 (13.4\%) | 0 (0.0\%) |  |
| Interstitial abnormalities |  |  | <0.001 |
| 0 | 37 (55.2\%) | 2 (13.3\%) |  |
| Undet | 1 (1.5\%) | 0 (0.0\%) |  |
| 1 | 17 (25.4\%) | 13 (86.7\%) |  |
| not mentioned | 1 (1.5\%) | 0 (0.0\%) |  |
| na | 11 (16.4\%) | 0 (0.0\%) |  |
| CT_Ground-glass opacities |  |  | 0.96 |


| 1 | 13 (19.4\%) | 3 (20.0\%) |  |
| :---: | :---: | :---: | :---: |
| na | 54 (80.6\%) | 12 (80.0\%) |  |
| CT_Local patchy shadowing |  |  | 0.76 |
| 0 | 5 (7.5\%) | 1 (6.7\%) |  |
| 1 | 5 (7.5\%) | 2 (13.3\%) |  |
| na | 57 (85.1\%) | 12 (80.0\%) |  |
| CT_Diffuse patchy shadowing |  |  | 0.96 |
| 0 | 6 (9.0\%) | 1 (6.7\%) |  |
| 1 | 4 (6.0\%) | 1 (6.7\%) |  |
| na | 57 (85.1\%) | 13 (86.7\%) |  |
| CT_Pleural effusion |  |  | 0.17 |
| 0 | 7 (10.4\%) | 0 (0.0\%) |  |
| 1 | 5 (7.5\%) | 3 (20.0\%) |  |
| na | 55 (82.1\%) | 12 (80.0\%) |  |
| CT_Interstitial abnormalities |  |  | 0.85 |
| 0 | 5 (7.5\%) | 2 (13.3\%) |  |
| 1 | 6 (9.0\%) | 1 (6.7\%) |  |
| 60 | 1 (1.5\%) | 0 (0.0\%) |  |
| na | 55 (82.1\%) | 12 (80.0\%) |  |
| N_med, mean (SD) | 2.36 (2.09) | 3.07 (2.37) | 0.25 |
| N_med |  |  | 0.14 |
| 0 | 16 (23.9\%) | 1 (6.7\%) |  |
| 1 | 15 (22.4\%) | 2 (13.3\%) |  |
| 2 | 8 (11.9\%) | 5 (33.3\%) |  |
| 3 | 5 (7.5\%) | 1 (6.7\%) |  |
| 4 | 11 (16.4\%) | 4 (26.7\%) |  |
| 5 | 6 (9.0\%) | 1 (6.7\%) |  |
| 6 | 4 (6.0\%) | 0 (0.0\%) |  |
| 7 | 2 (3.0\%) | 0 (0.0\%) |  |
| 10 | 0 (0.0\%) | 1 (6.7\%) |  |
| N_med1 |  |  | 0.25 |
| 0 | 16 (23.9\%) | 1 (6.7\%) |  |
| 1 | 15 (22.4\%) | 2 (13.3\%) |  |
| 2 | 8 (11.9\%) | 5 (33.3\%) |  |
| 3 | 5 (7.5\%) | 1 (6.7\%) |  |
| 4 | 11 (16.4\%) | 4 (26.7\%) |  |
| 55 | 12 (17.9\%) | 2 (13.3\%) |  |
| Remdesivir | 3 (4.5\%) | 1 (6.7\%) | 0.72 |
| Hydroxychloroquine | 10 (14.9\%) | 5 (33.3\%) | 0.096 |
| azithromycin | 44 (65.7\%) | 10 (66.7\%) | 0.94 |
| Statin | 17 (25.4\%) | 7 (46.7\%) | 0.10 |
| Corticosteroid | 21 (31.3\%) | 4 (26.7\%) | 0.72 |
| ACEi/ARB | 7 (10.4\%) | 3 (20.0\%) | 0.31 |
| Vit C | 23 (34.3\%) | 1 (6.7\%) | 0.033 |
| Zinc | 20 (29.9\%) | 1 (6.7\%) | 0.063 |


| Vitamin D | $12(17.9 \%)$ | $2(13.3 \%)$ | 0.67 |
| :--- | ---: | ---: | ---: |
| Vasopressors | $1(1.5 \%)$ | $8(53.3 \%)$ | $<0.001$ |
| Tocilizumab | $0(0.0 \%)$ | $2(13.3 \%)$ | $\mathbf{0 . 0 0 2}$ |
| convalescent plasma | $0(0.0 \%)$ | $2(13.3 \%)$ | $\mathbf{0 . 0 0 3}$ |

SD: standard deviation;
IQR: inter-quartile range

SuppI. Table 3. Unadjusted association between ICU admission and selected cofactors.

| ICU admission |  |  |  |
| :---: | :---: | :---: | :---: |
| Factor | No | Yes | p-value |
| N | 62 | 20 |  |
| Age, mean (SD) | 52.63 (17.87) | 62.25 (13.97) | 0.031 |
| BMI, mean (SD) | 29.59 (5.31) | 30.69 (6.63) | 0.46 |
| Maximum body temperature |  |  |  |
| recorded, mean (SD) | 37.95 (0.88) | 39.31 (1.16) | <0.001 |
| Respiratory rate (highest), mean (SD) | 23.79 (7.72) | 58.85 (15.12) | <0.001 |
| Systolic, mean (SD) | 107.09 (22.34) | 69.85 (25.99) | <0.001 |
| Diastolic, mean (SD) | 62.20 (12.62) | 39.40 (14.88) | <0.001 |
| Lowest SpO2 recorded, mean (SD) | 88.77 (7.36) | 62.39 (22.96) | <0.001 |
| Hb , mean (SD) | 13.36 (2.68) | 10.61 (3.00) | <0.001 |
| WBC count, median (IQR) | 6.77 (4.45, 9.61) | $\begin{array}{r} 14.63 \text { (11.88, } \\ 17.07) \end{array}$ | <0.001 |
| Lymphocyte count, median (IQR) | 0.88 (0.59, 1.30) | $\begin{array}{r} 0.59(0.40 \\ 0.80) \end{array}$ | 0.008 |
|  |  | 315.00 |  |
| Platelet count, median (IQR) | $\begin{array}{r} 224.00(170.00 \\ 322.00) \end{array}$ | $\begin{aligned} & (163.50 \\ & 458.50) \end{aligned}$ | 0.16 |
|  |  | 568.00 |  |
|  | 371.50 (282.50, | (336.00, |  |
| LDH, median (IQR) | 456.50) | 734.00) | 0.073 |
|  | 10.85 (5.90, | 18.00 (7.50, |  |
| CRP, median (IQR) | 16.40) | 18.00) | 0.025 |
| Procalcitonin, median (IQR) | 0.09 (0.05, 0.18) | $\begin{array}{r} 0.41(0.21 \\ 2.18) \end{array}$ | <0.001 |
| Lactic acid , median (IQR) | 1.10 (0.80, 1.80) | $\begin{array}{r} 2.50(1.50 \\ 4.40) \end{array}$ | 0.006 |
| HCO3, mean (SD) | 21.70 (4.29) | 24.15 (19.58) | 0.39 |
|  | 50.00 (33.00, | 84.50 (65.50, |  |
| AST, median (IQR) | 71.00) | 237.50) | <0.001 |
|  | 39.00 (22.00, | 58.50 (41.50, |  |
| ALT, median (IQR) | 74.00) | 106.50) | 0.022 |
|  |  | 1.30 (1.15, |  |
| INR , median (IQR) | 1.20 (1.10, 1.30) | 1.40) | 0.12 |
|  | 30.95 (27.30, | 36.70 (33.10, |  |
| PTT, median (IQR) | 32.75) | 70.10) | 0.031 |
| Bil total, median |  | $0.90 \text { (0.65, }$ |  |
|  | $48.50 \text { (40.00, }$ |  | 0.090 |
| CK, median (IQR) | 157.00) | 383.50) | 0.17 |
| Na , mean (SD) | 135.45 (5.39) | 130.00 (30.89) | 0.21 |
|  |  | 5.30 (3.60, |  |
| K , median (IQR) | 4.10 (3.60, 4.70) | 6.35) | 0.008 |


| Cl , median (IQR) | $\begin{array}{r} 103.00(98.00 \\ 108.00) \end{array}$ | $\begin{array}{r} 107.50(91.00 \\ 113.50) \end{array}$ | 0.75 |
| :---: | :---: | :---: | :---: |
| D-Dimer, median |  | $5.93 \text { (2.65, }$ |  |
|  | 1.02 (0.63, 1.74) | $\begin{array}{r} 11.79) \\ 788.50 \end{array}$ | <0.001 |
| PRO-BNP, median (IQR) | $\begin{array}{r} 467.00(131.00, \\ 887.00) \end{array}$ | $\begin{array}{r} (304.00, \\ 17690.00) \end{array}$ | 0.56 |
|  |  | 4601.67 |  |
| Lipase, mean (SD) | 263.14 (210.85) | (4133.51) | 0.016 |
| TROPONIN, median (IQR) | 0.01 (0.01, 0.01) | $\begin{array}{r} 0.03 \text { (0.01, } \\ 0.16) \end{array}$ | 0.003 |
| pH , mean (SD) | 7.40 (0.10) | 7.27 (0.19) | 0.036 |
|  | 55.30 (27.90, | 59.90 (46.80, |  |
| PO2, median (IQR) | 64.20) | 77.80) | 0.38 |
|  | 37.90 (32.20, | 39.30 (28.60, |  |
| PCO2, median (IQR) | 39.60) | 59.30) | 0.47 |
| Sex |  |  | 0.42 |
| F | 28 (45.2\%) | 7 (35.0\%) |  |
| M | 34 (54.8\%) | 13 (65.0\%) |  |
| Pregnancy | 2 (3.2\%) | 0 (0.0\%) | 0.42 |
| Current smokers | 3 (4.8\%) | 1 (5.0\%) | 0.98 |
| Drug use | 2 (3.2\%) | 1 (5.0\%) | 0.71 |
| IVDU | 1 (1.6\%) | 0 (0.0\%) | 0.57 |
| Alcoholic | 2 (3.3\%) | 1 (5.0\%) | 0.72 |
| Recent travel to | (27.4\%) | (30.0\%) | 0.82 |
| Recent contact with |  |  |  |
| COVID-19 + case | 12 (19.4\%) | 5 (25.0\%) | 0.59 |
| Duration between exposure and symptoms if known |  |  | 0.72 |
| 0 | 60 (96.8\%) | 20 (100.0\%) |  |
| 2 | 1 (1.6\%) | 0 (0.0\%) |  |
| 7 | 1 (1.6\%) | 0 (0.0\%) |  |
| Any positive family member/roommate | 14 (22.6\%) | 2 (10.0\%) | 0.22 |
| Any episode of fever | 43 (69.4\%) | 17 (85.0\%) | 0.17 |
| What was the first started symptom? |  |  | 0.45 |
| AMS | 1 (1.6\%) | 0 (0.0\%) |  |
| Anosmia | 1 (1.6\%) | 0 (0.0\%) |  |
| Cough | 1 (1.6\%) | 0 (0.0\%) |  |
| Hypoxia | 1 (1.6\%) | 0 (0.0\%) |  |
| SOB | 2 (3.2\%) | 1 (5.0\%) |  |
| Shortness of |  |  |  |
| breath | 4 (6.5\%) | 3 (15.0\%) |  |
| abdominal pain anosmia and | 0 (0.0\%) | 1 (5.0\%) |  |
| ageusia | 1 (1.6\%) | 0 (0.0\%) |  |


| body aches coffee-ground | 1 (1.6\%) | 0 (0.0\%) |  |
| :---: | :---: | :---: | :---: |
| emesis | 1 (1.6\%) | 0 (0.0\%) |  |
| cough | 14 (22.6\%) | 2 (10.0\%) |  |
| cough \& headache | 1 (1.6\%) | 0 (0.0\%) |  |
| cough and SOB | 1 (1.6\%) | 0 (0.0\%) |  |
| cough and fever | 0 (0.0\%) | 1 (5.0\%) |  |
| cough or fever | 1 (1.6\%) | 0 (0.0\%) |  |
| diarrhea | 1 (1.6\%) | 0 (0.0\%) |  |
| dry cough | 1 (1.6\%) | 0 (0.0\%) |  |
| epigastric pain | 1 (1.6\%) | 0 (0.0\%) |  |
| fatigue | 2 (3.2\%) | 0 (0.0\%) |  |
| fatigue/weakness | 1 (1.6\%) | 0 (0.0\%) |  |
| fever | 3 (4.8\%) | 1 (5.0\%) |  |
| itchy throat left-sided | 1 (1.6\%) | 0 (0.0\%) |  |
| weakness loss of taste and | 0 (0.0\%) | 1 (5.0\%) |  |
| smell | 1 (1.6\%) | 0 (0.0\%) |  |
| nasal congestion | 0 (0.0\%) | 1 (5.0\%) |  |
| productive cough | 1 (1.6\%) | 0 (0.0\%) |  |
| sore throat | 1 (1.6\%) | 0 (0.0\%) |  |
| throat pain | 1 (1.6\%) | 0 (0.0\%) |  |
| weakness | 0 (0.0\%) | 1 (5.0\%) |  |
| weakness/fatigue | 0 (0.0\%) | 1 (5.0\%) |  |
|  | 18 (29.0\%) | 7 (35.0\%) |  |
| N_symptoms, mean (SD) | 4.94 (2.90) | 3.90 (2.86) | 0.17 |
| Conjunctival congestion |  |  |  |
| 0 | 62 (100.0\%) | 20 (100.0\%) |  |
| Nasal congestion | 10 (16.1\%) | 2 (10.0\%) | 0.50 |
| Rhinorrhea | 1 (1.6\%) | 2 (10.0\%) | 0.082 |
| Headache | 21 (34.4\%) | 5 (25.0\%) | 0.43 |
| Cough | 42 (67.7\%) | 13 (65.0\%) | 0.82 |
| Sore throat | 15 (24.2\%) | 3 (15.0\%) | 0.39 |
| Sputum production | 9 (14.5\%) | 2 (10.0\%) | 0.61 |
| Fatigue | 26 (41.9\%) | 11 (55.0\%) | 0.31 |
| Hemoptysis | 1 (1.6\%) | 0 (0.0\%) | 0.57 |
| Shortness of breath | 41 (66.1\%) | 14 (70.0\%) | 0.75 |
| chest pain | 21 (33.9\%) | 3 (15.0\%) | 0.11 |
| chest discomfort | 11 (17.7\%) | 1 (5.0\%) | 0.16 |
| abdominal pain | 6 (9.7\%) | 2 (10.0\%) | 0.97 |
| Nausea or vomiting | 23 (37.1\%) | 4 (20.0\%) | 0.16 |
| Diarrhea | 15 (24.6\%) | 5 (25.0\%) | 0.97 |
| Myalgia or arthralgia | 26 (41.9\%) | 4 (20.0\%) | 0.077 |


| Chill | 23 (37.1\%) | 4 (20.0\%) | 0.16 |
| :---: | :---: | :---: | :---: |
| loss of taste | 8 (12.9\%) | 1 (5.0\%) | 0.33 |
| loss of smell | 7 (11.3\%) | 2 (10.0\%) | 0.87 |
| N_signs, mean (SD) | 0.45 (0.64) | 0.60 (0.68) | 0.38 |
| N_signs |  |  | 0.59 |
| 0 | 39 (62.9\%) | 10 (50.0\%) |  |
| 1 | 18 (29.0\%) | 8 (40.0\%) |  |
| 2 | 5 (8.1\%) | 2 (10.0\%) |  |
| Throat congestion | 3 (4.8\%) | 0 (0.0\%) | 0.32 |
| Tonsil swelling | 3 (4.8\%) | 1 (5.0\%) | 0.98 |
| Rash | 2 (3.2\%) | 1 (5.0\%) | 0.71 |
| Abnormal lung sounds | 18 (30.0\%) | 9 (45.0\%) | 0.22 |
| N_chronic, mean (SD) | 1.16 (1.23) | 2.20 (1.24) | 0.002 |
| N_chronic |  |  | 0.040 |
| 0 | 25 (40.3\%) | 2 (10.0\%) |  |
| 1 | 14 (22.6\%) | 2 (10.0\%) |  |
| 2 | 15 (24.2\%) | 10 (50.0\%) |  |
| 3 | 5 (8.1\%) | 3 (15.0\%) |  |
| 4 | 2 (3.2\%) | 2 (10.0\%) |  |
| 5 | 1 (1.6\%) | 1 (5.0\%) |  |
| N_chronic1 |  |  | 0.010 |
| 0 | 25 (40.3\%) | 2 (10.0\%) |  |
| 1 | 14 (22.6\%) | 2 (10.0\%) |  |
| 2 | 15 (24.2\%) | 10 (50.0\%) |  |
| 33 | 8 (12.9\%) | 6 (30.0\%) |  |
| COPD | 1 (1.6\%) | 1 (5.0\%) | 0.39 |
| DM | 17 (27.4\%) | 15 (75.0\%) | <0.001 |
| HTN | 27 (43.5\%) | 13 (65.0\%) | 0.095 |
| Coronary artery disease | 4 (6.5\%) | 4 (20.0\%) | 0.076 |
| Cerebrovascular disease | 3 (4.8\%) | 3 (15.0\%) | 0.13 |
| Cancer | 1 (1.6\%) | 0 (0.0\%) | 0.57 |
| CKD | 4 (6.5\%) | 3 (15.0\%) | 0.23 |
| Cirrhosis | 1 (1.6\%) | 0 (0.0\%) | 0.57 |
| Asthma | 3 (4.8\%) | 1 (5.0\%) | 0.98 |
| Rheumatological | 1 (1.6\%) | 0 (0.0\%) | 0.57 |
| IBD | 0 (0.0\%) | 1 (5.0\%) | 0.076 |
| HIV+ | 0 (0.0\%) | 1 (5.0\%) | 0.076 |
| Hepatitis | 2 (3.2\%) | 0 (0.0\%) | 0.42 |
| Hypothyroidism | 8 (13.1\%) | 2 (10.0\%) | 0.71 |
| Hyperthyroidism |  |  |  |
| 0 | 61 (98.4\%) | 20 (100.0\%) |  |
|  | 1 (1.6\%) | 0 (0.0\%) |  |


| Ground-glass opacities |  |  | 0.031 |
| :---: | :---: | :---: | :---: |
| 0 | 26 (41.9\%) | 5 (25.0\%) |  |
| 1 | 27 (43.5\%) | 15 (75.0\%) |  |
| 99 | 9 (14.5\%) | 0 (0.0\%) |  |
| Local patchy shadowing |  |  | 0.17 |
| 0 | 30 (48.4\%) | 10 (50.0\%) |  |
| 1 | 23 (37.1\%) | 10 (50.0\%) |  |
| 99 | 9 (14.5\%) | 0 (0.0\%) |  |
| Diffuse patchy shadowing |  |  | <0.001 |
| 0 | 40 (64.5\%) | 4 (20.0\%) |  |
| 1 | 13 (21.0\%) | 16 (80.0\%) |  |
| 99 | 9 (14.5\%) | 0 (0.0\%) |  |
| Pleural effusion |  |  | <0.001 |
| 0 | 47 (75.8\%) | 8 (40.0\%) |  |
| 1 | 6 (9.7\%) | 12 (60.0\%) |  |
| 99 | 9 (14.5\%) | 0 (0.0\%) |  |
| Interstitial abnormalities |  |  | 0.002 |
| 0 | 35 (56.5\%) | 4 (20.0\%) |  |
| 0 ? | 1 (1.6\%) | 0 (0.0\%) |  |
| 1 | 15 (24.2\%) | 15 (75.0\%) |  |
| ?? Looks like it but |  |  |  |
| not mentioned | 1 (1.6\%) | 0 (0.0\%) |  |
| na | 10 (16.1\%) | 1 (5.0\%) |  |
| CT_Ground-glass opacities |  |  | 0.48 |
| 1 | 11 (17.7\%) | 5 (25.0\%) |  |
| na | 51 (82.3\%) | 15 (75.0\%) |  |
| CT_Local patchy shadowing |  |  | 0.83 |
| 0 | 4 (6.5\%) | 2 (10.0\%) |  |
| 1 | 5 (8.1\%) | 2 (10.0\%) |  |
| na | 53 (85.5\%) | 16 (80.0\%) |  |
| CT_Diffuse patchy shadowing |  |  | 0.14 |
| 0 | 6 (9.7\%) | 1 (5.0\%) |  |
| 1 | 2 (3.2\%) | 3 (15.0\%) |  |
| na | 54 (87.1\%) | 16 (80.0\%) |  |
| CT_Pleural effusion |  |  | 0.18 |
| 0 | 6 (9.7\%) | 1 (5.0\%) |  |
| 1 | 4 (6.5\%) | 4 (20.0\%) |  |
| na | 52 (83.9\%) | 15 (75.0\%) |  |
| CT_Interstitial abnormalities |  |  | 0.34 |


| 0 | 5 (8.1\%) | 2 (10.0\%) |  |
| :---: | :---: | :---: | :---: |
| 1 | 5 (8.1\%) | 2 (10.0\%) |  |
| 60 | 0 (0.0\%) | 1 (5.0\%) |  |
| na | 52 (83.9\%) | 15 (75.0\%) |  |
| N_med, mean (SD) | 2.26 (2.09) | 3.20 (2.21) | 0.088 |
| N_med |  |  | 0.062 |
| 0 | 16 (25.8\%) | 1 (5.0\%) |  |
| 1 | 15 (24.2\%) | 2 (10.0\%) |  |
| 2 | 6 (9.7\%) | 7 (35.0\%) |  |
| 3 | 4 (6.5\%) | 2 (10.0\%) |  |
| 4 | 11 (17.7\%) | 4 (20.0\%) |  |
| 5 | 5 (8.1\%) | 2 (10.0\%) |  |
| 6 | 3 (4.8\%) | 1 (5.0\%) |  |
| 7 | 2 (3.2\%) | 0 (0.0\%) |  |
| 10 | 0 (0.0\%) | 1 (5.0\%) |  |
| N_med1 |  |  | 0.048 |
| 0 | 16 (25.8\%) | 1 (5.0\%) |  |
| 1 | 15 (24.2\%) | 2 (10.0\%) |  |
| 2 | 6 (9.7\%) | 7 (35.0\%) |  |
| 3 | 4 (6.5\%) | 2 (10.0\%) |  |
| 4 | 11 (17.7\%) | 4 (20.0\%) |  |
| 55 | 10 (16.1\%) | 4 (20.0\%) |  |
| Remdesivir | 1 (1.6\%) | 3 (15.0\%) | 0.016 |
| Hydroxychloroquine | 9 (14.5\%) | 6 (30.0\%) | 0.12 |
| azithromycin | 41 (66.1\%) | 13 (65.0\%) | 0.93 |
| Statin | 15 (24.2\%) | 9 (45.0\%) | 0.075 |
| Corticosteroid | 18 (29.0\%) | 7 (35.0\%) | 0.61 |
| ACEi/ARB | 8 (12.9\%) | 2 (10.0\%) | 0.73 |
| Vit C | 21 (33.9\%) | 3 (15.0\%) | 0.11 |
| Zinc | 18 (29.0\%) | 3 (15.0\%) | 0.21 |
| Vitamin D | 9 (14.5\%) | 5 (25.0\%) | 0.28 |
| Vasopressors | 0 (0.0\%) | 9 (45.0\%) | <0.001 |
| Tocilizumab | 0 (0.0\%) | 2 (10.0\%) | 0.012 |
| convalescent plasma | 0 (0.0\%) | 2 (10.0\%) | 0.012 |
| SD: standard deviation; IQR: inter-quartile range |  |  |  |

